• Home
  1. Home
  2. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma
Scientific article
English

Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma

ContributorsAlgazi, Alain P; Twitty, Christopher G; Tsai, Katy K; Le, Mai; Pierce, Robert; Browning, Erica; Hermiz, Reneta; Canton, David A; Bannavong, Donna; Oglesby, Arielle; Francisco, Murray; Fong, Lawrence; Pittet, Mikaëlorcid; Arlauckas, Sean P; Garris, Christopher; Levine, Lauren P; Bifulco, Carlos; Ballesteros-Merino, Carmen; Bhatia, Shailender; Gargosky, Sharron; Andtbacka, Robert H I; Fox, Bernard A; Rosenblum, Michael D; Daud, Adil I
Published inClinical Cancer Research, vol. 26, no. 12, p. 2827-2837
Publication date2020
Abstract

Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; "tavo") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).

Affiliation entities Not a UNIGE publication
Research groups
Citation (ISO format)
ALGAZI, Alain P et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. In: Clinical Cancer Research, 2020, vol. 26, n° 12, p. 2827–2837. doi: 10.1158/1078-0432.CCR-19-2217
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN1078-0432
218views
0downloads

Technical informations

Creation07/08/2021 5:05:00 PM
First validation07/08/2021 5:05:00 PM
Update time03/16/2023 1:05:16 AM
Status update03/16/2023 1:05:15 AM
Last indexation10/07/2025 9:25:24 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack